
Danish biotech firm Ascendis Pharma, which is listed in the US, wants to raise USD 500m by offering convertible notes, the company reports in a press release.
According to the company, the notes will mature in 2028 and are meant for ”qualified institutional buyers” pursuant to Securities and Exchange Commission (SEC) rules.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app